NH TherAguix announces the publication of promising preclinical results of AGuIX® in combination with targeted radioligand therapies (TRT)
NH TherAguix announcesthe publication of promising preclinical results of AGuIX® in combination with targeted radioligand therapies (TRT) in the Journal of Nuclear Medicine (October, 2023).
NH TherAguix and Jean PERRIN Cancer Centre in Clermont-Ferrand
announce the completion of phase I recruitment and the entry into Phase II for the Nano-GBM phase I/II trial in glioblastoma with the two first patients included.
NH TherAguix announces communications to be presented at the AAPM meeting by Harvard Medical School collaborators
NH TherAguix is happy to announce that 4 communications related to AGuIX will be provided during the American Association for Physicists in Medicine annual meeting in Houston, Texas, USA by our US collaborators
NH TherAguix announces the release of a new clinical batch for it’s drug AGuIX manufactured by CARBOGEN AMCIS
MEYLAN, France, BUBENDORF, Switzerland (November 3rd, 2021) – NH TherAguix, a clinical stage company developing innovative nanomedicine for the treatment of cancer, and CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today the release of a new batch of AGuIX Drug Product for clinical trials.
NH TherAguix announces the enrolment in Boston of the first 2 patients in its clinical trials NANOBRAINMETS and NANOSMART
Meylan (France) and Boston (US), October 1st, 2021 – NH TherAguix announces the enrolment of the 2 first patients in its clinical trials NANOBRAINMETS Phase II targeting brain metastasis and NANOSMART Phase Ib/II targeting pancreatic cancer and cancerous lung lesions.
NH TherAguix is pleased to announce that Fabien Boux which joined the Clinical Development Unit as Biomedical Engineer in January, was awarded with the Ph. D. prize 2020 of the Société Française de Résonance Magnétique en Biologie et Médecine (“SFRMBM”).
NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial
NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy on multiple brain metastases patients – Grenoble (France), May 31, 2021 – 11:00 pm (CET)
NH TherAguix, a start-up specializing in nanomedicine for cancer radiotherapy, announces a €13 million round of fundraising, led by Bpifrance – Grenoble/Lyon/Paris (France) – 11 April 2019